Posted by Michael Wonder on 26 Aug 2025
Enhertu approved in Japan as first HER2 directed medicine for patients with HER2 low or HER2 ultra-low metastatic breast cancer following at least one endocrine therapy
25 August 2025 - Based on DESTINY-Breast06 phase 3 trial results that showed Enhertu demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year.
Enhertu (trastuzumab deruxtecan) has been approved in Japan for the treatment of adult patients with hormone receptor positive, HER2 low (IHC 1+ or IHC 2+/ISH-) or HER2 ultra-low (IHC 0 with membrane staining) unresectable or recurrent breast cancer.
